Current and Future Cost Burden of Ischemic Stroke in Australia: Dynamic Model.

IF 3.2 3区 医学 Q2 CLINICAL NEUROLOGY Neuroepidemiology Pub Date : 2024-01-01 Epub Date: 2024-04-01 DOI:10.1159/000538564
Tamrat Befekadu Abebe, Jenni Ilomaki, Adam Livori, J Simon Bell, Jedidiah I Morton, Zanfina Ademi
{"title":"Current and Future Cost Burden of Ischemic Stroke in Australia: Dynamic Model.","authors":"Tamrat Befekadu Abebe, Jenni Ilomaki, Adam Livori, J Simon Bell, Jedidiah I Morton, Zanfina Ademi","doi":"10.1159/000538564","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Stroke remains one of the leading causes of morbidity and mortality in Australia. The objective of this study was to estimate the current and future cost burden of ischemic stroke (IS) in Australia.</p><p><strong>Method: </strong>First, the annual chronic management cost per person following IS were derived for all people aged ≥30 years discharged from a public or private hospital in Victoria, Australia between July 2012 and June 2017 (with follow-up data until June 2018 [n = 34,471]). Then extrapolated the data from from Victoria to the whole Australian population aged between 30 years and 99 years to project the total healthcare costs following IS (combination of acute event and chronic management cost) over a 20-year period (2019-2038) using a dynamic multistate life table model. Data for the dynamic model were sourced from the Victorian Admitted Episodes Dataset (VAED) and supplemented with other published data.</p><p><strong>Result: </strong>The estimated annual total chronic management cost following IS was 13,525 Australian dollars (AUD) per person (95% CI: AUD 13,380, AUD 13,670) for cohorts in the VAED between July 2012 and June 2017. The annual chronic management cost was estimated to decline following IS. The highest cost was incurred in the first year of follow-up post-IS (AUD 14,309 per person) and declined to AUD 9,776 in the sixth year of follow-up post-IS. The total healthcare cost for people aged 30-99 years was projected to be AUD 47.7 billion (95% UI: AUD 44.6 billion, AUD 51.0 billion) over the 20-year period (2019-2038) Australia-wide, of which 91.3% (AUD 43.6 billion) was attributed to chronic management costs and the remaining 8.7% (AUD 4.2 billion) were due to acute IS events.</p><p><strong>Conclusion: </strong>IS has and will continue to have a considerable financial impact in the next 2 decades on the Australian healthcare system. Our estimated and projected cost burden following IS provides important information for decision making in relation to IS.</p>","PeriodicalId":54730,"journal":{"name":"Neuroepidemiology","volume":" ","pages":"358-368"},"PeriodicalIF":3.2000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11449186/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuroepidemiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000538564","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/4/1 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Stroke remains one of the leading causes of morbidity and mortality in Australia. The objective of this study was to estimate the current and future cost burden of ischemic stroke (IS) in Australia.

Method: First, the annual chronic management cost per person following IS were derived for all people aged ≥30 years discharged from a public or private hospital in Victoria, Australia between July 2012 and June 2017 (with follow-up data until June 2018 [n = 34,471]). Then extrapolated the data from from Victoria to the whole Australian population aged between 30 years and 99 years to project the total healthcare costs following IS (combination of acute event and chronic management cost) over a 20-year period (2019-2038) using a dynamic multistate life table model. Data for the dynamic model were sourced from the Victorian Admitted Episodes Dataset (VAED) and supplemented with other published data.

Result: The estimated annual total chronic management cost following IS was 13,525 Australian dollars (AUD) per person (95% CI: AUD 13,380, AUD 13,670) for cohorts in the VAED between July 2012 and June 2017. The annual chronic management cost was estimated to decline following IS. The highest cost was incurred in the first year of follow-up post-IS (AUD 14,309 per person) and declined to AUD 9,776 in the sixth year of follow-up post-IS. The total healthcare cost for people aged 30-99 years was projected to be AUD 47.7 billion (95% UI: AUD 44.6 billion, AUD 51.0 billion) over the 20-year period (2019-2038) Australia-wide, of which 91.3% (AUD 43.6 billion) was attributed to chronic management costs and the remaining 8.7% (AUD 4.2 billion) were due to acute IS events.

Conclusion: IS has and will continue to have a considerable financial impact in the next 2 decades on the Australian healthcare system. Our estimated and projected cost burden following IS provides important information for decision making in relation to IS.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
澳大利亚缺血性中风当前和未来的成本负担:动态模型。
背景:中风仍是澳大利亚发病和死亡的主要原因之一。本研究旨在估算澳大利亚缺血性中风(IS)当前和未来的成本负担:首先,对 2012 年 7 月至 2017 年 6 月期间从澳大利亚维多利亚州公立或私立医院出院的所有年龄≥ 30 岁的患者(n = 34 471)进行了缺血性中风后的慢性管理成本计算。然后利用这些成本,使用动态多州生命表模型预测澳大利亚 30 至 99 岁人群在 20 年内(2019-2038 年)发生 IS 后的总成本(急性事件和慢性管理成本的组合)。动态模型的数据来自维多利亚州入院病例数据集(VAED),并辅以其他已公布的数据:在2012年7月至2017年6月期间的VAED中,IS后的年度慢性管理总成本估计为每人13525澳元(95%CI:13380澳元,13670澳元)。据估计,IS后每年的慢性病管理成本将有所下降。IS后第一年的随访成本最高(每人14 309澳元),IS后第六年的随访成本降至9 776澳元。预计在 20 年期间(2019-2038 年),全澳大利亚 30-99 岁人群的医疗保健总成本为 477 亿澳元(95% UI:446 亿澳元,510 亿澳元),其中 91.3% (436 亿澳元)为慢性管理成本,其余 8.7% (42 亿澳元)为急性 IS 事件成本:IS已经并将在未来二十年继续对澳大利亚医疗保健系统产生巨大的经济影响。我们估计和预测的 IS 成本负担为 IS 相关决策提供了重要信息。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Neuroepidemiology
Neuroepidemiology 医学-公共卫生、环境卫生与职业卫生
CiteScore
9.90
自引率
1.80%
发文量
49
审稿时长
6-12 weeks
期刊介绍: ''Neuroepidemiology'' is the only internationally recognised peer-reviewed periodical devoted to descriptive, analytical and experimental studies in the epidemiology of neurologic disease. The scope of the journal expands the boundaries of traditional clinical neurology by providing new insights regarding the etiology, determinants, distribution, management and prevention of diseases of the nervous system.
期刊最新文献
Rising Prevalence of Multiple Sclerosis in Switzerland - Results from the Swiss Multiple Sclerosis Registry. Disease burden of Parkinson's disease in Asia and its 34 countries and territories from 1990 to 2021: findings from the Global Burden of Disease Study 2021. Increased Survival in Contemporary Parkinson's Disease - a 47 year autopsy study. Forecasting the Worldwide Impact of Stroke for individuals aged 45 and above. Analysis of Stroke Burden in China from 1990 to 2021 and Projections for the Next Decade.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1